Melanoma with Brain Mets | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Brain metastases, a particular type of Stage IV melanoma, are among the most common and difficult melanoma side effects. Brain metastases are distinct from all other metastases in terms of risk factors, diagnosis, and therapy. The third most common cause of cerebral metastases, behind lung and breast cancer, is malignant melanoma. The central nervous system (CNS) metastases affect 10% to 40% of melanoma patients. Malignant melanoma is the third most common cause of cerebral metastases, after lung and breast cancer. Among melanoma patients, the central nervous system (CNS) metastases occur in 10-40% of cases.

Description

Brain metastases are a specific type of Stage IV melanoma and one of the most common and difficult melanoma side effects. Brain metastases are distinct from all other metastases in terms of risk factors, diagnosis, and therapy. Prior to recently, the outlook for melanoma brain metastases was grim, with a median overall survival of just four to five months. The good news is that systemic therapy and advancements in radiation therapy are giving some patients with this challenging condition hope for a recovery. In the past, patients with a single brain metastasis who received effective treatment had a higher chance of long-term survival than patients with many metastatic tumors.

Melanoma with Brain Mets (Epidemiology)

Malignant melanoma is the third most common cause of cerebral metastases, behind lung and breast cancer. Metastases to the central nervous system (CNS) occur in 10-40% of melanoma patients. Melanoma brain metastases (MBM) are directly responsible for death in 60-70% of melanoma patients. They are common and have a very dismal outlook. 1302166 patients were diagnosed with cancer between 2010 and 2013, and 217 687 of them went on to develop metastatic disease to any distant site. A total of 26430 patients, or 2% of all cancer patients and 12.1 % of those with metastatic disease, had brain metastases at the time of diagnosis. Given that SEER accounts for 28% of the population in the US, we can estimate the annual incidence of identified brain metastases in patients with newly diagnosed cancer to be 23598 per year (95% CI: 23297-23899). There were notable variations in the proportion of patients with brain metastases at diagnosis depending on the primary cancer type. When all cancers of any stage were taken into account, only small cell lung cancer, adenocarcinoma of the lung, and non-small cell lung cancer not otherwise specified/other lung cancer had an incidence proportion of brain metastases at diagnosis of >10% (15.8%, 14.4%, and 12.8%, respectively). At the time of diagnosis, only 0.4%, 1.5%, and 0.7% of patients with breast cancer, renal cancer, and melanoma, respectively, had brain metastases.

Melanoma with Brain Mets-Current Market Size & Forecast Trends

The market for treating melanoma with brain metastases is expected to grow significantly through 2035, driven by rising melanoma cases, advancements in targeted therapies and immunotherapies, and improved diagnostics. Key factors include ongoing research, better healthcare access, and increased awareness and screening programs, making this a rapidly expanding segment in oncology.

Malignant melanoma is the third most common cause of cerebral metastases, behind lung and breast cancer. The central nervous system (CNS) metastases affect 10% to 40% of melanoma patients. Whole brain radiotherapy may be helpful palliatively when a patient has numerous brain metastases. If feasible, a multidisciplinary team of melanoma experts should treat melanoma patients with brain metastases by determining the best combination and sequencing of surgery, radiotherapy, and systemic therapy. When formulating a treatment plan, it is important to consider prognostic elements such as the quantity and symptoms of cerebral metastases, serum LDH and S100 values, extracerebral metastasis, and ECOG (Eastern Cooperative Oncology Group) status. Interdisciplinary or multimodal approaches should be used when selecting or carrying out the therapy. Brain metastases that are isolated can be treated with stereotactic radiation and neurosurgical removal. Treatment options have significantly increased as a result of the approval of effective immunotherapies (such as CTLA-4 and PD-1 antibodies) and targeted therapies (such as BRAF and MEK inhibitors). Palliative whole brain radiation is employed in a number of symptomatic brain metastases even though no discernible benefit for overall survival has yet been shown. In cases of increased intracranial pressure and epileptic seizures, corticosteroids and anticonvulsants are advised. Some of the novel therapeutic options being investigated in current clinical trials for melanoma patients with brain metastases include PD-1 antibodies, ipilimumab plus nivolumab, BRAF inhibitors plus MEK inhibitors, stereotactic radiosurgery combined with immunotherapy, or targeted therapy.

Report Highlights

Melanoma with Brain Mets- Current Market Trends

Melanoma with Brain Mets- Current & Forecasted Cases across the G8 Countries

Melanoma with Brain Mets- Market Opportunities and Sales Potential for Agents

Melanoma with Brain Mets- Patient-based Market Forecast to 2035

Melanoma with Brain Mets- Untapped Business Opportunities

Melanoma with Brain Mets- Product Positioning Vis-a-vis Competitors' Products

Melanoma with Brain Mets- KOLs Insight